If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...

Question: I have recently been diagnosed with sciatica and I am finding it difficult to do any exercise. My usual form of ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The city council honored a Lake Forest police canine, described as "invaluable," who recently retired following a medical ...

The Lake County Sheriff's Office said Wednesday that "exciting news" will be announced relating to a canine, which comes following the death of famed Canine Dax last year.

[s5] A diffuse gadolinium enhancement of the lumbosacral nerve roots and cauda equina could be found in childhood-onset Krabbe disease [s6] and metachromatic leucodystrophy,[s7] whereas in adult-onset ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...